• How DTP3 Connects GADD45β to JNK Apoptosis

  2026-10-22

  DTP3 is described as an inhibitor of the GADD45β/MKK7 complex that links NF-κB-associated survival signaling to JNK activation and apoptosis. The reported evidence spans biochemical binding, tumor-cell selectivity, and myeloma xenograft growth suppression, but each level answers a different research question and does not independently establish clinical efficacy.

• How to Interpret p-Cresyl Sulfate Potassium

  2026-10-21

  p-Cresyl sulfate potassium is best interpreted first as a defined chemical species: the potassium salt of the sulfate-conjugated p-cresyl group. Its identity can guide measurement interpretation, but the available product documentation does not establish a biological mechanism, treatment effect, or study outcome.

• SUGCT Inhibition and the GA1 Drug-Discovery Case

  2026-10-20

  Wu et al. combined structural biology, a coupled SUGCT activity assay, and engineered human-cell models to examine SUGCT as a modifiable biochemical determinant in glutaric aciduria type 1. The study supports target plausibility and identifies chemical inhibitors, but it does not establish cellular target engagement, therapeutic efficacy, or clinical repositioning.

• How SOAT1 Links Lipid Dysregulation to PHMG Fibrosis

  2026-10-19

  Ding et al. reported that PHMG-associated pulmonary fibrosis in mice was accompanied by alveolar-macrophage foaming, altered cholesterol handling, SOAT1 upregulation, and impaired lipophagy. The study’s use of Filipin III supported assessment of cellular free-cholesterol distribution, while avasimibe-based perturbation strengthened—but did not by itself complete—the causal case for SOAT1.

• Oxiconazole (Nitrate): Evidence and Mechanism

  2026-10-19

  The APExBIO product page identifies Oxiconazole (nitrate) as an imidazole-derivative antifungal compound and attributes several mechanistic, tissue-distribution, animal-model, and clinical claims to the product description. Because no identity-matched research paper is available here, those claims are treated as documented supplier information rather than independently verified research findings.

• When Context Changes a Cholesterol Readout

  2026-10-18

  Filipin III staining in a preclinical pulmonary-fibrosis study was a context-dependent readout of cellular free-cholesterol distribution, not a standalone demonstration of total cholesterol burden or SOAT1 causality. Interpreting the result requires separating the material’s measurement properties from the biological model, comparator, lipid pool, and evidence limitations.

• AR Heterogeneity in Castration-Resistant Prostate Cancer

  2026-10-17

  Li et al. linked distinct androgen-receptor expression states to different castration and enzalutamide responses in castration-resistant prostate cancer. Their evidence combined patient-tissue immunohistochemistry, xenograft models, genetically matched AR-positive and AR-knockout cells, transcriptomic analysis, and biochemical studies. The work supports AR status as a biologically meaningful source of treatment heterogeneity, while leaving important boundaries: immunostaining is not equivalent to pathway activity, the models do not capture the full clinical diversity of metastatic disease, and the therapeutic findings were not clinical validation. Mifepristone (RU486) is a separate progesterone-receptor antagonist and was not identified as a material used in this study.

• IKK-16: What the Record Supports

  2026-10-16

  The available product information identifies IKK-16, also called IKK Inhibitor VII, as APExBIO product B1586, but provides no identity-matched research paper or documented mechanistic, potency, selectivity, or outcome data. The label suggests an intended relationship to IKK inhibition; it does not independently establish a molecular target, pathway effect, or experimental performance.

• Filipin III and the SOAT1–Fibrosis Evidence Gap

  2026-10-16

  A source-grounded interpretation of how Filipin III staining contributed to a 2026 preclinical study of PHMG-induced pulmonary fibrosis, what the SOAT1 findings establish, and why the cholesterol readout does not by itself resolve causality or clinical relevance.

• Recombinant Human TNF-alpha: Scope and Evidence

  2026-10-15

  The APExBIO product description identifies PH1010 as a tag-free, non-glycosylated recombinant human Tumor Necrosis Factor-alpha (TNF-alpha/TNFSF2) produced in Escherichia coli. It describes trimer-dependent biological activity, signaling through two receptor types, and a cytotoxicity-based potency claim, but it does not provide an identity-matched research paper or pathway-resolved evidence that would support broader performance conclusions.

• BV6: A Proportionate Mechanism Overview

  2026-10-15

  APExBIO describes BV6 as a Smac-mimetic IAP antagonist associated with apoptosis-related and sensitization phenotypes in selected cancer-cell models and with disease-suppression signals in a mouse endometriosis model. The available information supports a product-level mechanistic overview, but not an independent assessment of efficacy, selectivity, clinical relevance, or comparative performance.

• Nadolol (SQ-11725): Mechanism and Evidence Scope

  2026-10-14

  APExBIO’s listing identifies Nadolol (SQ-11725) as a non-selective beta-adrenergic receptor blocker and an OATP1A2 substrate, but no identity-matched study supplies outcome data. This editorial separates catalog claims from research evidence, clarifies the interpretation of heart-rate and blood-pressure readouts, and defines the product’s applicability boundaries.

• Nitazoxanide and Pulmonary Vascular Remodeling

  2026-10-14

  A 2026 Toxicology and Applied Pharmacology study proposes that nitazoxanide may reduce pulmonary hypertension-associated vascular remodeling through an IMPA1–RAGE signaling axis. Its findings are mechanistically suggestive but remain limited to experimental models and cellular systems; they do not establish clinical efficacy or prove that the reported effects are mediated exclusively through IMPA1–RAGE.

• Cyanine 3 Tyramide and Threat-Circuit Evidence

  2026-10-13

  A source-grounded overview separates the documented scope of Cyanine 3 Tyramide as a fluorescence-labeling reagent from emerging mouse evidence linking early life adversity to oxytocin-dependent defensive behavior. The study supports a circuit-level hypothesis, but its in-press status, model specificity, and limited translational evidence constrain broader conclusions.

• Sinapine, Oxidative Stress and C2C12 Cell Death

  2026-10-13

  A 2024 cell-based study examined whether sinapine protects C2C12 myoblasts from oxidant-associated injury and explored links among MAPK signaling, reactive oxygen species and autophagy. The findings support a protective association in this defined in vitro model, but do not establish efficacy in muscle tissue, animals or humans, nor do they show that sinapine directly targets any single pathway.

8621 records 1/575 page Next 12345 下5页 Last page